Alberto Bardelli

Alberto Bardelli is a Full Professor at the Department of Oncology, University of Torino, and Scientific Director at IFOM (The AIRC Institute of Molecular Oncology) in Milan. He holds academic roles in programs such as the Molecular Medicine PhD Program and the MD-PhD Program. His research focuses on cancer genomics, liquid biopsies, and targeted therapies, particularly in colorectal cancer. Notable contributions include identifying kinase mutations in colorectal cancer and pioneering liquid biopsy applications to monitor tumor evolution and resistance. He has published over 250 articles in top journals like Nature and Science, and led the PEGASUS clinical trial. Awards include the Guido Venosta Award and membership in prestigious organizations like EMBO and EACS.

• Education: PhD in Biochemistry from University College London (UCL), postdoc at Johns Hopkins University under Bert Vogelstein.
• Research Interests: Tumor genomics, drug resistance mechanisms, immunotherapy, and precision medicine.

His articles highlight advancements in liquid biopsies, immunogenic therapies, and molecular vulnerabilities in cancer. He leads initiatives like the PEGASUS trial, which uses ctDNA to guide adjuvant treatments in colon cancer. His work bridges basic research and clinical applications, influencing global oncology practices.

• Awards: Guido Venosta Award (2020), Web of Science Highly Cited Researcher (2014–present).
• Labs/Teams: Molecular Biotechnology Center (MBC2), IRCC Candiolo, and IFOM.